MedTrace Logo

A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

NCT07230119 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 744

Last updated 2025-12-23

No results posted yet for this study

Summary

This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.

Conditions

  • Overweight , Obesity

Interventions

DRUG

Zovaglutide dose 1

administered subcutaneously (SC), Q4W

DRUG

Zovaglutide dose 2

administered subcutaneously (SC), Q4W

DRUG

Placebo

administered subcutaneously (SC), Q4W

Sponsors & Collaborators

  • Beijing QL Biopharmaceutical Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Linong Ji, MD · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-08
Primary Completion
2027-05-29
Completion
2027-06-26

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07230119 on ClinicalTrials.gov